Melane Sampson, Author at BioTuesdays

Developments

HOOKIPA completes enrollment in Phase 1b study of HB-500 in HIV

HOOKIPA Pharma (NASDAQ:HOOK) has announced the completion of enrollment for its Phase 1b trial evaluating HB-500 in patients with HIV. The company stated that the study is comprised of two dose-escalation cohorts, with...

January 30, 2025

Developments

Tectonic announces positive Phase 1b results for TX45 in HFpEF

Tectonic Therapeutic (NASDAQ:TECX) has announced positive interim data from its Phase 1b acute hemodynamic clinical trial of TX45 in Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH...

January 30, 2025

Developments

Polyrizon files patent application with ILPO for T&T technology

Polyrizon (NASDAQ:PLRZ) has announced the filing of a patent application for its advanced intranasal drug delivery system Trap & Target (T&T) technology, with the Israel Patent Office (ILPO). The company stated...

January 30, 2025

Developments

Model Medicines unveils AI-driven pipeline breakthrough; demonstrates end-to-end drug discovery capabilities

Closely held Model Medicines has announced the unveiling of a generative AI-driven, multi-modal therapeutic pipeline breakthrough, showcasing its end-to-end drug discovery capabilities for novel target discovery...

January 28, 2025

Developments

NLS launches preclinical program for Mazindol ER in fentanyl addiction

NLS Pharmaceutics (NASDAQ:NLSP; NASDAQ:NLSPW) has announced the launch of a preclinical program to evaluate Mazindol ER as a novel treatment for fentanyl dependence. According to the Centers for Disease Control and...

January 28, 2025

Developments

Conduit partners with Sarborg to advance drug development with AI

Conduit Pharmaceuticals (NASDAQ:CDT) has announced that the first phase in its collaboration with Sarborg, aimed at integrating advanced AI and cybernetics technology into its operations has been completed. The company...

January 28, 2025

Executive Moves

Samir Hussein joins Ladenburg Thalmann in TMT investment banking

Ladenburg Thalmann has announced the appointment of Samir Hussein as managing director, TMT investment banking, based in New York. Mr. Hussein brings more than two decades of investment banking experience advising...

January 28, 2025

Developments

RenovoRX highlights abstract showcasing promising PK data for TAMP in LAPC

RenovoRX (NASDAQ:RNXT) has announced that an abstract presented at the ASCO Gastrointestinal Cancers Symposium 2025 highlights promising pharmacokinetic (PK) data from its patented Trans-Arterial Micro-Perfusion (TAMP)...

January 27, 2025

Developments

Greenwich adds Harvard and Johns Hopkins sites to Phase 3 trial

Greenwich LifeSciences (NASDAQ:GLSI) has announced the launch of two new clinical sites for its FLAMINGO-01 Phase 3 trial of GLSI-100 in HER2 breast cancer, including Harvard and Johns Hopkins Universities...

January 23, 2025

Developments

EMA grants IRLAB waiver from pediatric studies of mesdopetam in PD

IRLAB Therapeutics (STO:IRLAB-A; FRA:6IRA) has announced that the European Medicines Agency (EMA) has granted a waiver allowing the company to bypass pediatric studies of mesdopetam, enabling a focus on patient groups...

January 23, 2025

Author - Melane Sampson

HOOKIPA completes enrollment in Phase 1b study of HB-500 in HIV

Tectonic announces positive Phase 1b results for TX45 in HFpEF

Polyrizon files patent application with ILPO for T&T technology

Model Medicines unveils AI-driven pipeline breakthrough; demonstrates end-to-end drug discovery capabilities

NLS launches preclinical program for Mazindol ER in fentanyl addiction

Conduit partners with Sarborg to advance drug development with AI

Samir Hussein joins Ladenburg Thalmann in TMT investment banking

RenovoRX highlights abstract showcasing promising PK data for TAMP in LAPC

Greenwich adds Harvard and Johns Hopkins sites to Phase 3 trial

EMA grants IRLAB waiver from pediatric studies of mesdopetam in PD

Subscribe